CPAP therapy significantly reduces the risk of death for people with obstructive sleep apnea, according to a landmark meta-analysis supported by Resmed and published in The Lancet Respiratory Medicine ...
Resmed (NYSE: RMD) announced today that it began a comprehensive brand evolution to unify its brand portfolio.
ResMed has launched a rebrand to unify its portfolio and reflect its increasing direct-to-consumer engagement.
ResMed showed 29% EPS growth last quarter. Sales gains came in at 10%. ResMed earns the No. 6 rank among its peers in the ...
Stifel lowered the firm’s price target on ResMed (RMD) to $240 from $250 and keeps a Hold rating on the shares. After having gathered survey ...
ResMed's fifth annual Global Sleep Survey highlights a significant global sleep crisis, revealing that 71% of employed individuals have called in sick at least once due to poor sleep, with the ...
“For people with OSA, using CPAP versus not using CPAP can literally be a matter of life or death,” said Carlos Nunez, M.D., Resmed’s Chief Medical Officer. “Decades of research have shown CPAP can ...